Lineage Cell Therapeutics (LCTX) Intangibles (2010 - 2026)

Lineage Cell Therapeutics' Intangibles history runs 17 years deep, the most recent figure standing at $31.7 million for Q1 2026.

• On a quarterly basis, Intangibles changed N/A year-over-year to $31.7 million in Q1 2026; TTM through Mar 2026 was $31.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $31.7 million, down 31.89% from the prior year.
• Intangibles steadied at $31.7 million in Q1 2026 per LCTX's latest filing, from $31.7 million in the prior quarter.
• Across five years, Intangibles topped out at $66.1 million in Q4 2022 and bottomed at $31.7 million in Q3 2025.
• The 5-year median for Intangibles is $46.6 million (2023), against an average of $51.4 million.
• Across the five-year window, Intangibles soared 213.34% in 2022 and plunged 52.07% in 2025, its largest moves.
• Year by year, Intangibles stood at $66.1 million in 2022, then fell by 29.6% to $46.6 million in 2023, then retreated by 0.05% to $46.5 million in 2024, then sank by 31.89% to $31.7 million in 2025, then changed by 0.0% to $31.7 million in 2026.
• Per Business Quant, the three latest LCTX Intangibles figures stand at $31.7 million (Q1 2026), $31.7 million (Q4 2025), and $31.7 million (Q3 2025).